News & Updates
Filter by Specialty:
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
27 Jun 2022
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022
Diabetes, fertility treatment, family history up autism risk in infants
A recent Egypt study has identified several maternal and neonatal factors contributing to the risk of autism spectrum disorders (ASD) in infants, including the use of assisted fertility treatments, family medical history, and threatened abortion.